You are here

Bernstein Liebhard LLP Launches Uloric Lawsuit Investigation, After FDA Concludes Febuxostat Increases Risk for Heart-Related Death and Death from All Causes Compared to Alternative Gout Medication

NEW YORK, March 7, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices, is investigating potential legal claims on behalf of patients who died or were hospitalized for heart attacks, strokes, blood clots, and other serious cardiovascular events while using Uloric to treat gout.

"A recent study found that Uloric is associated with a higher risk of heart-related death and death from all causes compared to an alternative gout treatment," said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP. "Our attorneys are committed to ensuring that the victims of Uloric side effects are fairly and fully compensated for all of their injury-related damages."

The firm is now offering free, no-obligation Uloric lawsuit reviews to individuals who may have been harmed by this gout medication, or their surviving loved ones.

Uloric and Heart-Related Death

The U.S. Food & Drug Administration (FDA) approved Uloric (febuxostat) in 2009 to treat adults suffering from gout, a painful form of arthritis caused by excessive levels of uric acid in the blood.

Because pre-market clinical trials suggested febuxostat might be associated with a higher risk of heart problems compared to another gout drug called allopurinol (Zyloprim and Aloprim), the agency required Takeda Pharmaceuticals to include a "Warning and Precaution" on the Uloric label regarding the potential for serious cardiovascular events, including heart attacks, strokes, and heart-related deaths. The FDA also ordered Takeda to conduct an additional, post-approval clinical trial to further assess Uloric's cardiovascular side effects.

According to an FDA Drug Safety Communication issued in November 2017, initial findings from Takeda's trial suggested Uloric was associated with an increased risk of heart-related death and death from all causes compared to allopurinol.

In February 2019, the FDA ordered a new Black Box Warning for the Uloric label, after an in-depth review of the trial data led the agency to concluded that there was a higher risk of death with febuxostat versus alternative medications. The FDA also restricted Uloric's approved uses to patients who cannot tolerate or are not treated effectively with allopurinol.

Learn More About Filing a Uloric Lawsuit

You may be entitled to compensation if you or a loved one experienced serious heart problems potentially associated with Uloric, including:

  • Heart Attack
  • Stroke
  • Pulmonary Embolism (PE)
  • Deep-Vein Thrombosis (DVT)
  • Angina
  • Heart-Related Death

To learn more about filing a Uloric lawsuit, and to arrange for your free, no-obligation case review, please visit Bernstein Liebhard LLP's website or contact the office directly at 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP has been named to The National Law Journal's "Plaintiffs' Hot List" 13 times and listed in The Legal 500 for 10 consecutive years.

Bernstein Liebhard LLP 
10 East 40th Street 
New York, New York 10016 

ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information: 
Sandy A. Liebhard, Esq. 
Bernstein Liebhard LLP 
info (at)consumerinjurylawyers(dot)com

Cision View original content to download multimedia:

SOURCE Bernstein Liebhard LLP